PMID- 35090550
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220204
IS  - 1758-5996 (Print)
IS  - 1758-5996 (Electronic)
IS  - 1758-5996 (Linking)
VI  - 14
IP  - 1
DP  - 2022 Jan 28
TI  - Diagnostic significance of serum FGD5-AS1 and its predictive value for the 
      development of cardiovascular diseases in patients with type 2 diabetes.
PG  - 20
LID - 10.1186/s13098-022-00789-x [doi]
LID - 20
AB  - BACKGROUND: As a result of the continuous rise in the incidence of type 2 
      diabetes mellitus (T2DM), related cardiovascular diseases (CVDs) have been a main 
      healthy burden worldwide. This study aimed to investigate the potential role of 
      FGD5-AS1 as a biomarker for the diagnosis of T2DM and predicting cardiovascular 
      complications in T2DM. METHODS: Three hundred subjects were recruited in this 
      study, including 100 T2DM patients without CVDs, 100 T2DM patients with CVDs as 
      well as 100 healthy subjects. Plasma FGD5-AS1 level was quantified using RT-qPCR 
      assay. The correlation of FGD5-AS1 level with other key variables was assessed 
      using Pearson correlation analysis. ROC curve analysis was performed to evaluate 
      the diagnostic value of FGD5-AS1 for T2DM and related CVDs. The effect of 
      FGD5-AS1 on AC16 and HA-VSMCs was determined. RESULTS: FGD5-AS1 level showed a 
      stepwise decrease in individuals with T2DM and CVDs compared to healthy persons. 
      FGD5-AS1 was associated with BMI, systolic blood pressure, diastolic blood 
      pressure, fasting glucose, 2-h postprandial blood glucose, HbA1c, triglycerides, 
      usCRP, and HDL-cholesterol. The ROC analysis indicated FGD5-AS1 had a significant 
      overall predictive ability to diagnose T2DM, T2DM with CVDs, and the combination 
      of both. FGD5-AS1 increases the growth but alleviates apoptosis and fibrosis of 
      high glucose-induced AC16 cells. FGD5-AS1 attenuate the growth and calcification 
      but induced apoptosis of high glucose-treated HA-VSMC cells. CONCLUSIONS: These 
      results suggest that FGD5-AS1 are associated with T2DM and measuring FGD5-AS1 
      could potentially contribute to T2DM screening and prediction for risk of 
      cardiovascular complication.
CI  - (c) 2022. The Author(s).
FAU - Wang, Yongdi
AU  - Wang Y
AD  - Department of Endocrinology, Weihai Municipal Hospital, Cheeloo College of 
      Medicine, Shandong University, No. 70, Heping Road, Huancui District, Weihai, 
      264200, Shandong, China. wangyongdi01@163.com.
FAU - Wang, Jian
AU  - Wang J
AD  - Department of Laboratory, Yidu Central Hospital of Weifang, Weifang, Shandong, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220128
PL  - England
TA  - Diabetol Metab Syndr
JT  - Diabetology & metabolic syndrome
JID - 101488958
PMC - PMC8796623
OTO - NOTNLM
OT  - Cardiovascular complications
OT  - FGD5-AS1
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2022/01/30 06:00
MHDA- 2022/01/30 06:01
PMCR- 2022/01/28
CRDT- 2022/01/29 05:31
PHST- 2021/11/25 00:00 [received]
PHST- 2022/01/06 00:00 [accepted]
PHST- 2022/01/29 05:31 [entrez]
PHST- 2022/01/30 06:00 [pubmed]
PHST- 2022/01/30 06:01 [medline]
PHST- 2022/01/28 00:00 [pmc-release]
AID - 10.1186/s13098-022-00789-x [pii]
AID - 789 [pii]
AID - 10.1186/s13098-022-00789-x [doi]
PST - epublish
SO  - Diabetol Metab Syndr. 2022 Jan 28;14(1):20. doi: 10.1186/s13098-022-00789-x.